CROI 2012: The Long and Winding Road to a Cure for HIV
- Details
- Category: Search for a Cure
- Published on Friday, 13 April 2012 00:00
- Written by Matt Sharp
No one ever thought finding a cure for AIDS would be easy. Medical research is rarely clear-cut, and an HIV cure breakthrough will be a monumental achievement. Yet at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012), there were significant signs that AIDS cure research is on its way up a long and winding road at the foot of a very big hill. While a functional cure (ability to control HIV without antiretroviral treatment) or total HIV eradication (known as sterilizing cure) may be a steep climb, advances in this field may improve the current state of HIV treatment.
CROI 2012: HIV+ People with CD4 Counts Above 500 Match Life Expectancy of General Population
- Details
- Category: HIV Treatment
- Published on Friday, 13 April 2012 00:00
- Written by Liz Highleyman
People with HIV who respond well to antiretroviral therapy (ART) and achieve undetectable viral load and a CD4 T-cell count above 500 cells/mm3 can have a mortality rate similar to that of HIV negative people, but this is not the case for those with 350-500 cells/mm3, according to a study presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle.
CROI 2012: Crofelemer Reduces Diarrhea in People with HIV; FDA Grants Priority Review
- Details
- Category: GI, Metabolic & Lipodystrophy
- Published on Tuesday, 10 April 2012 00:00
- Written by Liz Highleyman
A plant compound known as crofelemer significantly decreased the frequency of secretory diarrhea in HIV positive patients, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle. The U.S. Food and Drug Administration (FDA) has given crofelemer priority review status and is expected to take action by early June.
CROI 2012: Switching to Tenofovir Increases Bone Turnover, Raltegravir Can Improve Bone Density
- Details
- Category: Bone Loss
- Published on Tuesday, 10 April 2012 00:00
- Written by Liz Highleyman
HIV positive people who substituted tenofovir (Viread) for zidovudine (AZT; Retrovir) in their antiretroviral regimen showed elevated levels of biomarkers associated with bone turnover and decreased bone mineral density (BMD), researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle. A related study found that switching from tenofovir to raltegravir (Isentress) led to increases in bone density.
CROI 2012: How Detrimental Is Low but Detectable HIV Viral Load?
- Details
- Category: HIV Treatment
- Published on Tuesday, 03 April 2012 00:00
- Written by Liz Highleyman
Having low but detectable viral load is associated with problems including cardiovascular disease and cancer in people with HIV, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle.
More Articles...
- CROI 2012: ART Liver Toxicity is Lower with Modern Regimens, but Still a Risk for HIV/HCV Coinfected
- CROI 2012: HIV Treatment May Reduce Mother-to-Child Hepatitis C Transmission
- CROI 2012: San Francisco Early HIV Treatment Policy Linked to Lower Viral Load, Higher CD4 Count
- CROI 2012: Zinc Finger HIV Gene Therapy Moves Ahead
Web Design and Development by